ARQT

Arcutis Biotherapeutics, Inc. [ARQT] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

ARQT Stock Summary

Top 10 Correlated ETFs

ARQT


Top 10 Correlated Stocks

ARQT


In the News

08:00 29 Mar 2024 ARQT

Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference

Arcutis today announced that Arcutis management will participate in the 23rd Annual Needham Virtual Healthcare Conference, taking place April 8-11, 2024.

10:56 29 Mar 2024 ARQT

Arcutis Biotherapeutics, Inc. (ARQT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Arcutis Biotherapeutics, Inc. (ARQT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

10:56 29 Mar 2024 ARQT

Wall Street Analysts See a 54.78% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 54.8% in Arcutis Biotherapeutics, Inc. (ARQT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

10:56 29 Mar 2024 ARQT

Wall Street Analysts See a 58.85% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High?

The consensus price target hints at a 58.9% upside potential for Arcutis Biotherapeutics, Inc. (ARQT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

10:46 29 Mar 2024 ARQT

Is Arcutis Biotherapeutics (ARQT) Outperforming Other Medical Stocks This Year?

Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Athira Pharma, Inc. (ATHA) have performed compared to their sector so far this year.

05:00 29 Mar 2024 ARQT

Arcutis to Present at the TD Cowen 44th Annual Health Care Conference

WESTLAKE VILLAGE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the TD Cowen 44th Annual Health Care Conference.

08:00 29 Mar 2024 ARQT

Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results

Arcutis today announced that it will report its fourth quarter and full year financial results and provide a business update on Tuesday, February 27, 2024.

12:41 29 Mar 2024 ARQT

3 Once-in-a-Lifetime Biotech Stocks With Unprecedented Surge Potential

The biotech sector is one of my favorite sectors since it is not only constantly growing and with companies that are always doing wonderful research, products, and solutions, but it is also a sector that is constantly innovating and contributing to the health of the human being. If you want to participate as an investor in this sector and take advantage of companies that have great growth opportunities, here are three biotech stocks with potential that you can consider adding to your portfolio.

08:00 29 Mar 2024 ARQT

Arcutis to Present at the Guggenheim Healthcare Talks – 6th Annual Biotechnology Conference

WESTLAKE VILLAGE, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the Guggenheim Healthcare Talks – 6th Annual Biotechnology Conference.

03:09 29 Mar 2024 ARQT

Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture

Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture

ARQT Financial details

Company Rating
Neutral
Market Cap
1.08B
Income
-261.78M
Revenue
59.61M
Book val./share
0.96
Cash/share
2.95
Dividend
-
Dividend %
-
Employees
296
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-0.92
Forward P/E
-6.48
PEG
0.28
P/S
7.79
P/B
5.35
P/C
3.36
P/FCF
-1.83
Quick Ratio
5.89
Current Ratio
6.72
Debt / Equity
2.28
LT Debt / Equity
2.28
-
-
EPS (TTM)
-3.91
EPS next Y
-1.53
EPS next Q
-0.74
EPS this Y
-35.27%
EPS next Y
-60.81%
EPS next 5Y
-156.01%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-64.51%
EPS Q/Q
-1.37%
-
-
-
-
SMA20
-
SMA50
150%
SMA100
400%
Inst Own
89.63%
Inst Trans
0.76%
ROA
-93%
ROE
-228%
ROC
-0.99%
Gross Margin
93%
Oper. Margin
-506%
Profit Margin
-553%
Payout
-
Shs Outstand
114.97M
Shs Float
104.94M
-
-
-
-
Target Price
32
52W Range
1.76-15.4
52W High
-33.93%
52W Low
+891%
RSI
55
Rel Volume
0.69
Avg Volume
5.39M
Volume
3.72M
Perf Week
-2.65%
Perf Month
6.56%
Perf Quarter
113.12%
Perf Half Y
69.98%
-
-
-
-
Beta
1.152
-
-
Volatility
0.27%, 0.63%
Prev Close
0%
Price
9.91
Change
2.48%

ARQT Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0000.070.86
Net income per share
-1.2-3.8-4.17-5.84-3.78
Operating cash flow per share
-1.22-3.17-3.53-4.68-3.56
Free cash flow per share
-1.23-3.18-3.55-5.11-3.57
Cash per share
2.897.977.837.443.94
Book value per share
-1.857.596.033.811.28
Tangible book value per share
-1.857.596.033.681.19
Share holders equity per share
-1.857.596.033.811.28
Interest debt per share
0.010.141.573.963.35
Market cap
764.4M1B1.02B814.48M223.86M
Enterprise value
701.38M943.23M1.01B963.38M340.45M
P/E ratio
-18.2-7.4-4.98-2.54-0.85
Price to sales ratio
000220.973.76
POCF ratio
-17.84-8.88-5.87-3.16-0.91
PFCF ratio
-17.72-8.85-5.83-2.9-0.9
P/B Ratio
-11.753.713.443.892.52
PTB ratio
-11.753.713.443.892.52
EV to sales
000261.365.71
Enterprise value over EBITDA
-16.33-6.91-4.87-3.26-1.42
EV to operating cash flow
-16.37-8.34-5.76-3.74-1.38
EV to free cash flow
-16.26-8.32-5.73-3.43-1.38
Earnings yield
-0.05-0.14-0.2-0.39-1.17
Free cash flow yield
-0.06-0.11-0.17-0.35-1.11
Debt to equity
00.020.260.972.28
Debt to assets
00.020.190.450.59
Net debt to EBITDA
1.470.440.09-0.5-0.49
Current ratio
20.3312.9612.0911.577.08
Interest coverage
000-19.27-8.11
Income quality
1.020.830.850.830.94
Dividend Yield
000.070.150
Payout ratio
00-0.35-0.380
Sales general and administrative to revenue
00033.130
Research and developement to revenue
00049.491.86
Intangibles to total assets
0000.020.02
Capex to operating cash flow
0.0100.010.090
Capex to revenue
000-6.32-0.01
Capex to depreciation
-1.51-2.63-2.19-24.93-0.23
Stock based compensation to revenue
0008.870.65
Graham number
7.0725.4823.7722.3710.43
ROIC
0.67-0.49-0.54-0.75-0.83
Return on tangible assets
-0.39-0.45-0.5-0.73-0.78
Graham Net
-2.027.25.623.270.66
Working capital
101.24M270.22M369.45M399.6M283.76M
Tangible asset value
-65.03M270.62M297.68M202.39M82.23M
Net current asset value
-65.57M265.18M292.3M197.71M77.73M
Invested capital
00.020.260.972.28
Average receivables
0255K436K4.41M17.13M
Average payables
1.6M4.27M7.25M8.09M10.41M
Average inventory
0-255K335K4.35M10.32M
Days sales outstanding
000837.54158.03
Days payables outstanding
2.63K5.73K3.52K4.27K715.44
Days of inventory on hand
0-409.12564.483.64K783.57
Receivables turnover
0000.442.31
Payables turnover
0.140.060.10.090.51
Inventory turnover
0-0.890.650.10.47
ROE
0.65-0.5-0.69-1.53-2.96
Capex per share
-0.01-0.01-0.02-0.42-0.01

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.050.050.080.620.15
Net income per share
-1.24-1.3-1.16-0.73-0.72
Operating cash flow per share
-1.17-1.31-1.08-0.71-0.61
Free cash flow per share
-1.17-1.31-1.09-0.71-0.61
Cash per share
6.725.434.373.682.95
Book value per share
3.442.281.310.760.96
Tangible book value per share
3.322.171.20.650.96
Share holders equity per share
3.442.281.310.760.96
Interest debt per share
3.443.443.443.442.27
Market cap
902.2M672.86M585.43M327.77M299.03M
Enterprise value
1.05B794.83M684.54M425.37M415.63M
P/E ratio
-2.98-2.11-2.06-1.83-1.13
Price to sales ratio
304.69241.95112.88.622.11
POCF ratio
-12.7-8.37-8.81-7.45-5.32
PFCF ratio
-12.67-8.37-8.77-7.44-5.32
P/B Ratio
4.34.827.277.023.37
PTB ratio
4.34.827.277.023.37
EV to sales
354.98285.81131.911.1630.73
Enterprise value over EBITDA
-16.14-10.88-10.76-12.44-6.84
EV to operating cash flow
-14.79-9.89-10.3-9.67-7.39
EV to free cash flow
-14.77-9.88-10.25-9.66-7.39
Earnings yield
-0.08-0.12-0.12-0.14-0.22
Free cash flow yield
-0.08-0.12-0.11-0.13-0.19
Debt to equity
0.971.462.544.392.28
Debt to assets
0.450.540.640.70.59
Net debt to EBITDA
-2.29-1.67-1.56-2.86-1.92
Current ratio
11.579.938.436.727.08
Interest coverage
-9.9-10.83-9.08-4.88-7.88
Income quality
0.9910.940.980.85
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
16.762.088.861.250
Research and developement to revenue
11.4412.714.860.691.76
Intangibles to total assets
0.020.020.020.020.02
Capex to operating cash flow
00000
Capex to revenue
-0.04-0.03-0.0500
Capex to depreciation
-0.35-0.23-0.72-0.17-0.02
Stock based compensation to revenue
3.133.412.040.260.65
Graham number
9.88.195.843.513.93
ROIC
-0.17-0.22-0.26-0.15-0.21
Return on tangible assets
-0.17-0.21-0.23-0.16-0.2
Graham Net
2.951.740.760.040.5
Working capital
399.6M330.65M272.21M239.66M283.76M
Tangible asset value
202.39M132.73M73.7M40.09M82.23M
Net current asset value
197.71M127.95M68.69M35.31M77.73M
Invested capital
0.971.462.544.392.28
Average receivables
5.44M10.61M14.99M18.31M22.61M
Average payables
8.75M10.66M14.82M15.17M12.59M
Average inventory
5.91M8.03M9.51M12.19M13.52M
Days sales outstanding
257.08413.24298.3945.86171.72
Days payables outstanding
1.64K1.44K1.99K1K441.6
Days of inventory on hand
1.39K982.871.21K1.06K483.66
Receivables turnover
0.350.220.31.960.52
Payables turnover
0.050.060.050.090.2
Inventory turnover
0.060.090.070.080.19
ROE
-0.36-0.57-0.88-0.96-0.75
Capex per share
00000

ARQT Frequently Asked Questions

What is Arcutis Biotherapeutics, Inc. stock symbol ?

Arcutis Biotherapeutics, Inc. is a US stock , located in Westlake village of Ca and trading under the symbol ARQT

Is Arcutis Biotherapeutics, Inc. buy or a sell ?

3 stock analysts have 3 predictions with a medium analyst target price of $32. The lowest prediction is $8 and the highest is $51

What is ARQT stock prediction ?

With a median analyst target price of $8, 1 stock analysts have made 1 forecasts in last 90 days. $8 is the lowest and $8 is the greatest projection.

What is Arcutis Biotherapeutics, Inc. stock quote today ?

Arcutis Biotherapeutics, Inc. stock price is $9.91 today.

Is Arcutis Biotherapeutics, Inc. stock public?

Yes, Arcutis Biotherapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap